DE-GEMPHARMATECH
25.4.2022 14:32:08 CEST | Business Wire | Press release
GemPharmatech LLC is pleased to announce that on April 25, 2022, its parent company, GemPharmatech Co., Ltd., went public on the STAR MARKET of the Shanghai Stock Exchange under the stock code 688046. The initial offering included 50,000,000 ordinary shares at a public offering price of￥22.53 ($3.51) per share.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005235/en/
GemPharmatech, established on December 29, 2017, is a high-tech enterprise specializing in the research and development of laboratory animal models, production, technical services, and upstream and downstream industry expansion. In order to meet the rapid development needs of biomedical research and new drug development, the company has constructed more than 20,000 commercial mouse models with independent intellectual property rights, becoming the world's largest collection of mouse strains. These models promote research and development breakthroughs in the fields of gene function identification, disease mechanism analysis, drug target discovery, drug efficacy screening and verification, and provides a solution to the bottleneck of animal model technology. GemPharmatech has established subsidiaries in Beijing, Foshan, Chengdu, Changzhou, Guangzhou, and Shanghai, as well as a US subsidiary, GemPharmatech LLC. The company’s facilities include 30,000+ square meters of SPF-level facilities.
Models That Defy the Impossible
According to Dr. Xiang Gao, founder and Chairman of GemPharmatech Co. Ltd., “GemPharmatech will take this issuance and listing as an opportunity to keep up with the frontier trends of life science and new drug development, adhere to an R&D-driven strategy, continuously optimize the laboratory animal construct strategy and genetic engineering technology, and improve our preclinical service capabilities.”
“GemPharmatech will use the funds raised by the IPO for investment in key projects such as launching a germ-free mouse platform, and to further expand global market share and influence,” says US CEO Dr. Mark Moore. “The company is committed to providing the best service to our customers, promoting the development of the biopharmaceutical industry, and repaying the society, employees and investors through excellent business performance.”
About GemPharmatech
GemPharmatech is a leading provider of animal models and services to the global preclinical R&D community. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice. GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing, and customized breeding. The company has developed one of the world's largest collections of mouse models to enable scientific innovation and accelerate drug development. Learn more at gempharmatech.us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005235/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom